Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY2020 Earnings Presentation
14 slides from Morepen Laboratories's earnings presentation, Aug 13, 2019
Slide 1: Exchange filing cover letter
Date: 13/08/2019 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No: (022) 26598100 -8114 Phones: 91-22-22721233/4 Fax No: (022) 26598120 Fax: 91-22-2272
Slide 2: Investors Presentation (Q1'FY20) August 2019
“ I CHOOSE INVESTORS PRESENTATION (Q1’FY20) august 2019
Slide 3: Disclaimer
Disclaimer: This presen tation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situa tions or informa tional needs of any particula r person. This p resentation contains expressed o r implied forward l
Slide 4: Highlights of Q1'FY20 Performance
Highlights of Q1’FY20 Performance ₹ crores • Net Sales Revenue in Q1’FY20 up by 25.4% at Rs. 186.70 crore as compared to Q1’FY19 . • Net Profit after tax up by 256% at Rs. 8.41 crore against Rs.2.36 crores in Q1’FY19 . • Cash Profits up by 70% at Rs. 19.31 crore against Rs.11.38 crores last year sam
Slide 5: Segments wise growth
Segments wise growth: ₹ crores • Overall business for the Quarter (Q1’FY20) has gro wn at 24% as compared to Q1’FY19 203 • API Business has shown extremely good results having grown at 44% for the Q1’FY20 and still contributes 56% including its exports. 24% • Home Diagnostic Devices business which c
Slide 6: API: Export leads the way
API: Export leads the way ₹ crores • API Export business has got a jump of 50% with API Revenues • Montelukast registering 210% growth • Atorvastatin 57% growth 112,42 • New Molecules registering 346% growth • Domestic business has grew by 33% during the Q1’FY20 as 44% compared to Q1’FY19 at Rs. 32.
Slide 7: APAC Region outperforms
APAC Region outperforms ₹ crores • Asia pacific Export business has got 58% share in the export API Export business for the quarter and a jump of 79% as compared to Q1’FY19, with major growth registered from following markets: 79,50 • Bangladesh • Iran • China 50% • Japan • Israel • Thailand 53,19 •
Slide 8: Devices Business – Solid
Devices Business – Solid ₹ crores Performance • Home Devices portfolio has been growing with fast pace and has recorded a growth of 16% during the quarter. 40,03 • Blood Gluco Monitors have marked a gro wth of 30% in Q1’FY20 as against Q1’FY19. 16% Total Gluco monitors installed have crossed 3 milli
Slide 9: Prescription drugs sales up
Prescription drugs sales up ₹ crores • Overall Finished Dosages has not performed well in this quarter due to general slowdown and the business has declined by 6% in Q1’FY’20 as compared to last 25% 10,83 year same quarter. • Branded Prescription (Rx) products has grown by 25% during the Q1’FY’20 wi
Slide 10: OTC Business remains stable
OTC Business remains stable ₹ crores • Total OTC category has registered a growth of 6% during the quarter. 14,16 • OTC Brand Sharing and other lead brands Lemolate and Burnol have registered 6% decline during the quarter . 13,31 • ORS and Pain-X brands have grown by 88% and 44% respectively on a sm
Slide 11: Net Profit jumps many folds
Net Profit jumps many folds ₹ crores Net Standalone Revenue • EBIDTA number has grown up by 67% during the Quarter as compared to 189, corresponding Quarter last year 75 26% • Quantum jump in Cash Profits during Q1’FY20 and Cash surplus has increased by 70% as compared to Q1’FY19. 150, 91 • Net prof
Slide 12: Synopsis of Q1'FY20 Performance (Standalone)
Synopsis of Q1’FY20 Performance ₹ crores Standalone Standalone Y-o-Y Q1’FY20 Q1’FY19 Growth Net Revenue 189.75 150.91 25.7% Expenditure 170.02 139.10 22.2% EBIDTA 19.73 11.81 66.9% Interest 0.42 0.43 (2.1%) Cash Surplus 19.31 11.38 69.6% Dep. & Amortization 10.90 8.83 23.4% Income Tax - 0.19 - Net P
Slide 13: Synopsis of Q1'FY20 Performance (Consolidated)
Synopsis of Q1’FY20 Performance ₹ crores Consolidated Consolidated Y-o-Y Q1’FY20 Q1’FY19 Growth Net Revenue 203.26 163.80 24.1% Expenditure 183.65 151.55 21.1% EBIDTA 19.61 12.25 60.0% Interest 0.43 0.44 (3.3%) Cash Surplus 19.18 11.81 62.4% Dep. & Amortization 11.50 9.16 25.6% Income Tax 0.02 0.19
Slide 14: Thank You
Tank You Fa MOREPEN ‘The Joy Of Growing Together
Morepen Laboratories — Q1 FY2020 Earnings Presentation on 6ix